Calprotectin Elisa test (ALP/HRP)

Calprotectin ELISA Test (ALP/HRP)

CE-MARKED

The CALPRO Calprotectin ELISA Test (ALP/HRP) is a quantitative method for the determination of Calprotectin in stool samples and can be used as an aid in identifying organic disease of the small intestine, large bowel or the stomach in patients, to determine the disease activity and monitor the response to treatment in patients with ulcerative colitis or Crohn’s disease. In the literature Calprotectin determination has also be done in other body fluids, secretions and excretions, for instance serum, plasma or urine. The Calprotectin concentrations and protocols vary and have to be performed according to the published methods (e.g., Johne et al., 1997). The CALPRO Calprotectin ELISA Test (ALP) has only been validated for stool samples. In patients under treatment a normal Calprotectin value is an indicator that mucosal healing has been achieved. The test can also be used to predict clinical relapses. Functional disorders like irritable bowel disease, do not give increased fecal Calprotectin concentrations.

 

 


CALPRO TEAM

  • Anne Thjømøe

    Executive Chairman 

    Mail: athjomoe@calpro.no

    Direct line: +47 97 73 37 51

  • Anne Hancke Framstad

    Laboratory Quality Specialist

    E-mail: aframstad@calpro.no

    Direct line: +47 92 01 14 91

  • Einar Mørk

    Dir. Operations

    E-mail: einar@calpro.no

    Direct line: +47 47 28 55 61

  • Mona Schartum

    Production Manager

    E-Mail: mona.schartum@calpro.no

    Direct line: +47 93 22 73 63

  • Ingvild haukø bilde

    Ingvild Haukø

    Sales- and Marketing Manager

    e-mail: ingvild@calpro.no

    Direct line: +47 92 01 52 18

  • Ali Qamar

    Product Manager

    E-mail: ali@calpro.no

    Direct line: +47 41 17 81 19

General Information

Fecal calprotectin in differential diagnosis of irritable bowel syndrome

Li XG, Lv YM, Gu F, Yang XL., Department of Gastroenterology, Peking University Third May 9, 2015

PhiCal Test FDA approved

The PhiCal Test has now been approved by the FDA for clinical use in the USA October 1, 2014

Latest News

Calpro press release regarding MSD agreement

Please see the Calpro press release regarding MDS agreement for delivery of e-health technology CalproSmart:

Norsk | English October 13, 2016

Calprosmart in the Media

Please see our latest articles regarding CalproSmart in Aftenposten and LMF Norge

LMF Norge | Aftenposten October 12, 2016

View all latest

Share This